Relevance of multidrug resistance 1 and P-glycoprotein to drug resistance in patients with systemic lupus erythematosus

Histology and Histopathology

Volumn 22, Issue 4-6, 2007, Pages 465-468

  Tsujimura, S ^a   Saito, K ^a   Nakayamada, S ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Autoimmune disease; Lymphocytes; Multidrug resistance 1 gene; P glycoprotein; Systemic lupus erythematosus

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; BIOLOGICAL MARKER; DNA BINDING PROTEIN; NSEP1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

CELL STRESS; CYTOPLASM; DISEASE ACTIVITY; DRUG RELEASE; DRUG TARGETING; DRUG TRANSPORT; GENE OVEREXPRESSION; GENOTOXICITY; GLYCOPROTEIN SYNTHESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MULTIDRUG RESISTANCE; PERIPHERAL LYMPHOCYTE; PLASMAPHERESIS; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PHYSIOLOGY;

BIOLOGICAL MARKERS; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; P-GLYCOPROTEIN;

EID: 33947493895     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Advani R., Visani G., Milligan D., Saba H., Tallman M., Rowe J.M., Wiernik P.H., Ramek J., Dugan K., Luto B., Villena J., Davis E., Paietta E., Litchman M., Covelli A., Sikic B. and Greenberg P. (1999). Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv. Exp. Med. Biol. 457, 47-56.
2. Chaudhary P.M. and Roninson I.B. (1993). Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J. Natl. Cancer Inst. 85, 632-639.
3. Fisher G.A., Lum B.L., Hausdorff J. and Sikic B.I. (1996). Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 32A, 1082-1088.
4. Jorgensen C. and Maillefert J.F. (2000). Multidrug resistances genes in rheumatology. Is their role immunological or pharmacological? Joint Bone Spine 67, 6-10.
5. Kohno K., Sato S., Takano H., Matsuo K. and Kuwano M. (1989). The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem. Biophys. Res. Commun. 165, 1415-1421.
6. Kuwano M., Uchiumi T., Hayakawa H., Ono M., Wada M., Izumi H. and Kohno K. (2003). The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 94, 9-14.
7. Leonard G.D., Polgar O. and Bates S.E. (2002). ABC transportem and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs 3, 1652-1659.
8. List A.F., Kopecky K.J., Willman C.L., Head D.R., Slovak M.L., Douer D., Dakhil S.R. and Appelbaum F.R. (2002). Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100, 1910-1912.
9. McKeegan K.S., Borges-Walmsley M.I. and Walmsley A.R, (2003). The structure and function of drug pumps: an update. Trends Microbiol. 11, 21-29.
10. Meijer O.C., de Lange E.C., Breimer D.D., de Boer A.G., Workel J.O. and de Kloet E.R. (1998). Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-giycoprotein knockout mice. Endocrinol. 139, 1789-1793.
11. Miyazaki M., Kohno K., Uchiumi T., Tanimura H., Matsuo K., Nasu M. and Kuwano M. (1992). Activation of human multidrug resistance-1 gene promoter in response to heat shock stress. Biochem. Biophys. Res. Commun. 187, 677-684
12. Ohga T., Uchiumi T., Makino Y., Koike K., Wada M., Kuwano M. and Kohno K. (1998). Direct involvement of the Y-box binding protein YB-1 in genotoxic stress-induced activation of the human multidrug resistance 1 gene. J. Biol. Chem. 273, 5997-6000.
13. Tanimura H., Kohno K., Sato S., Uchiumi T., Miyazaki M., Kobayashi M. and Kuwano M. (1992). The human multidrug resistance 1 promoter has an element that responds to serum starvation. Biochem. Biophys. Res. Commun. 183, 917-924.
14. Tsujimura S., Saito K., Nakayamada S., Nakano K., Tsukada J., Kohno K. and Tanaka Y. (2004). Transcriptional regulation of multidrug resistance-1 gene by interleukin-2 in lymphocyte. Genes Cells 9, 1265-1273.
15. Tsujimura S., Saito K., Tokunaga M., Nakatsuka K., Nakayamada S., Nakano K. and Tanaka Y. (2005a). Overcoming treatment unresponsiveness mediated by P-glycoprotein overexpression on lymphocytes in refractory active systemic lupus erythematosus. Mod. Rheumatol. 15, 28-32.
16. Tsujimura S., Saito K., Nakayamada S., Nakano K. and Tanaka Y. (2005b). Clinical Relevance of the Expression of P-Glycoprotein on Peripheral Blood Lymphocytes to Steroid Resistance in Patients with Systemic Lupus Erythematosus. Arthritis Rheum. 52, 1676-1683.
17. Uchiumi T., Kohno K., Tanimura H., Matsuo K., Sato S., Uchida Y. and Kuwano M. (1993). Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. Cell Growth. Differ. 4, 147-157.